360 related articles for article (PubMed ID: 23546483)
1. Moving toward a more ideal anticoagulant: the oral direct thrombin and factor Xa inhibitors.
King CS; Holley AB; Moores LK
Chest; 2013 Apr; 143(4):1106-1116. PubMed ID: 23546483
[TBL] [Abstract][Full Text] [Related]
2. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
Dumont B; Faille D; Ajzenberg N
Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
[TBL] [Abstract][Full Text] [Related]
3. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
Contractor T; Levin V; Martinez MW; Marchlinski FE
Postgrad Med; 2013 Jan; 125(1):34-44. PubMed ID: 23391669
[TBL] [Abstract][Full Text] [Related]
4. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
5. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
6. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
7. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Graff J; Harder S
Clin Pharmacokinet; 2013 Apr; 52(4):243-54. PubMed ID: 23389892
[TBL] [Abstract][Full Text] [Related]
8. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
9. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
[TBL] [Abstract][Full Text] [Related]
10. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
Kakkos SK; Kirkilesis GI; Tsolakis IA
Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
[TBL] [Abstract][Full Text] [Related]
12. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Berman JP; Halperin JL
Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966
[TBL] [Abstract][Full Text] [Related]
13. New oral anticoagulants for the treatment of venous thromboembolism.
Agnelli G; Becattini C; Franco L
Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
[TBL] [Abstract][Full Text] [Related]
14. Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
Quinlan DJ; Eriksson BI
Best Pract Res Clin Haematol; 2013 Jun; 26(2):171-82. PubMed ID: 23953905
[TBL] [Abstract][Full Text] [Related]
15. New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.
Aguilar MI; Kuo RS; Freeman WD
Neurol Clin; 2013 Aug; 31(3):659-75. PubMed ID: 23896498
[TBL] [Abstract][Full Text] [Related]
16. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
Eriksson BI; Quinlan DJ; Eikelboom JW
Annu Rev Med; 2011; 62():41-57. PubMed ID: 21226611
[TBL] [Abstract][Full Text] [Related]
17. New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities.
Dobesh PP; Fanikos J
Drugs; 2014 Nov; 74(17):2015-32. PubMed ID: 25300410
[TBL] [Abstract][Full Text] [Related]
18. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS
Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161
[TBL] [Abstract][Full Text] [Related]
19. Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal.
Bauer KA
Stroke; 2013 Jun; 44(6 Suppl 1):S38-40. PubMed ID: 23709725
[No Abstract] [Full Text] [Related]
20. Practical aspects of new oral anticoagulant use in atrial fibrillation.
Undas A; Pasierski T; Windyga J; Crowther M
Pol Arch Med Wewn; 2014; 124(3):124-35. PubMed ID: 24556890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]